MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dopamine"

  • MDS Virtual Congress 2021

    Connectomic Analysis of SNc and VTA Projections to the Striatum and Cortex

    N. Handfield-Jones, A. Owen, A. Khan, P. Macdonald (London, Canada)

    Objective: To investigate the dopaminergic neural tracts of healthy individuals using Diffusion MRI on Human Connectome Project Data. Background: Classically, the DA system has been…
  • MDS Virtual Congress 2021

    The effects of acute administration of VMAT2 inhibitors on extracellular levels of dopamine, norepinephrine, 5-HT and histamine in the striatum and medial prefrontal cortex

    E. Adler, L. Magid, O. Even-Chen, S. Schmidt, I. Cope, J. Alexander, J. Kehr, A. Orbach (Netanya, Israel)

    Objective: To evaluate the effects of reversible VMAT2 inhibitors (deutetrabenazine, tetrabenazine and valbenazine) on extracellular levels of monoamines and their acidic metabolites in rat striatum…
  • MDS Virtual Congress 2021

    Istradefylline/L-DOPA combination therapy for Parkinson’s disease and blood markers of glycolytic energy homeostasis

    NAO. Kanzato, KO. Nakachi, MA. Hayashi, F. Kinjyo, W. Mizuta, SA. Mochizuki (Haebaru-Cho, Okinawa, Japan)

    Objective: To clarify the potential to preserve glycolytic energy homeostasis (GEH) with the Istradefylline combined to L-DOPA (IST-LD), and to prevent LD-induced weight loss and…
  • MDS Virtual Congress 2021

    OPTIMIPARK Questionnaire:a tool to optimize treatment in Parkinson´s disease.

    J. Máñez-Miró, F. Vivancos-Matellano, L. Vela-Desojo, R. Martinez-Fernandez, F. Alonso-Frech, N. Lopez-Aristegui, E. Balaguer-Martínez, J. Martinez-Castrillo, L. Lopez-Manzanares, P. Martínez-Martín (Madrid, Spain)

    Objective: To validate the OPTIMIPARK questionnaire as a tool to help the clinician in the adjustment of dopaminergic treatment in Parkinson´s disease(PD). Background: At early…
  • MDS Virtual Congress 2021

    Influence of Dopamine Transporter Gene Polymorphism on Wearing Off

    CE. Mantese, V. Altmann, A. Schumacher-Schuh, M. Hutz, CRM. Rieder (Porto Alegre, Brazil)

    Objective: To study the influence of Dopamine transporter gene polymorphism on Wearing off (WO) through 19 items wearing off questionnaire (WOQ-19) Background: The dopamine transporter…
  • MDS Virtual Congress 2021

    Parkinson’s Disease Medication Safety in the Inpatient Cohort of a Tertiary Centre

    A. Redmond, G. Richard, M. Penugonda, D. Bradley (Dublin 8, Ireland)

    Objective: Our study aimed to determine the accuracy of initial prescribing on hospital admission and the subsequent timing of administration of Parkinson’s disease (PD) medications…
  • MDS Virtual Congress 2021

    The responsiveness of arm swing to dopaminergic medication in Parkinson’s disease depends on task complexity

    E. Warmerdam, R. Romijnders, C. Hansen, M. Elshehabi, M. Zimmermann, F. Metzger, A. von Thaler, D. Berg, G. Schmidt, W. Maetzler (Kiel, Germany)

    Objective: The aim of this study is to analyse the responsiveness of arm swing during walking to dopaminergic medication in patients with Parkinson’s disease. Background:…
  • MDS Virtual Congress 2020

    Levodopa Changes Functional Connectivity Patterns in Subregions of the Primary Motor Cortex in Patients with Parkinson’s Disease

    Y.S Shen, W. Liu, M.Y Yu, W.L Liu (Nanjing, China)

    Objective: To investigated functional connectivity pattern changes in M1 subregions and relationships to improved clinical symptoms following levodopa administration. Background: The primary motor cortex (M1)…
  • MDS Virtual Congress 2020

    The role of dopamine mis-metabolism in preclinical Parkinson’s disease olfactory deficits

    L. Beauchamp, L. Vella, A. Bush, K. Barnham (Melbourne, Australia)

    Objective: To gain an understanding of the underlying pathological mechanisms of Parkinson’s disease (PD)-related hyposmia using post-mortem human olfactory bulbs and an in vivo model…
  • MDS Virtual Congress 2020

    Characterization of striatal dopaminergic neurotransmission in the rat pre-formed fibril models of Parkinson’s disease

    I. Del Priore, N. Chambers, M. Coyle, R. Fassler, J. Patterson, C. Kemp, A. Stoll, K. Miller, K. Luk, C. Sortwell, C. Bishop (Binghamton, NY, USA)

    Objective: To determine the longitudinal effects of synucleinopathy and synucleinopathy-triggered nigrostriatal degeneration on basal and evoked striatal dopamine (DA) release in the striatum at 4…
  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 27
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley